Antibody effective against mutations
Schlieren ZH - The MTX-COVAB antibody developed by Memo Therapeutics is effective against the original variant of the Sars-CoV-2 virus that causes coronavirus infections as well as the mutations that were first identified in the UK and South Africa. It is now being transferred to the clinical development phase.
Yova raises 11 million Swiss francs
Zurich - Yova has received a fresh capital injection totaling 11 million Swiss francs. The investors participating in the financing round are convinced that the start-up has really captured the Zeitgeist with its portal for sustainable investment. The investment will support expansion plans to further countries.
Building with repurposed material
Building with repurposed materials: At the NEST research and innovation building in the Greater Zurich Area, a model project is underway on this with business and research partners. An entire ecosystem is working on sustainable solutions to raise the material treasure of buildings with added value.
Researchers able to curb coronavirus growth
Zurich – An international team led by ETH Zurich has successfully generated molecule-precise insights into the replication mechanism of the coronavirus and how to inhibit this. The results could boost the development of drugs to combat the SARS-Cov-2 virus.
BC Platform cooperate with Artisan
Zurich - BC Platforms and Artisan Biomed have agreed a partnership. After securing access to the BC Platforms healthcare technology in the field of genetics, Artisan is now planning to drive forward the development of precision medicine in South Africa.
APR nasal spray being tested in coronavirus patients
Balerna TI – The pharmaceutical company Applied Pharma Research (APR) has announced the start of a clinical study with the nasal spray it has developed. This will investigate the efficacy of the medicinal device in treating COVID-19 patients with mild symptoms.
AI increases touch screen precision
Zurich – Researchers at the Swiss Federal Institute of Technology in Zurich have developed an artificial intelligence to enable super-resolution touch screens. This should enable cell phones and other devices to recognize where a finger touches the screen with significantly greater precision than before.
CDR-Life facing clinical phase for its immunotherapy
Schlieren ZH – The biotech company CDR-Life from the Greater Zurich Area has developed its immunotherapies to treat cancer up to the clinical phase. Immunotherapy is an alternative to chemotherapy in the treatment of cancer.
Synhelion aims to produce solar fuel from 2023
Lugano/London - The ETH spin-off Synhelion is collaborating with the British engineering group Wood. Together they plan to bring synthetic solar fuel to market more quickly. The market launch is scheduled for 2023.
Meet with an expansion expert
Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center? Give us a call or drop us a line.